CODEXIS Business Summary

Codexis, Inc. (CDXS) operates as a leading enzyme engineering company that generates revenue through a mix of high-performance enzyme product sales, research and development (R&D) collaboration fees, and strategic licensing agreements. The company is currently executing a significant strategic pivot, transitioning from a broad-based enzyme supplier to a specialized provider of manufacturing solutions for complex therapeutics. Its primary business segments include its heritage Pharma Biocatalysis business, which leverages the proprietary CodeEvolver® platform to optimize small-molecule API manufacturing, and its high-growth ECO Synthesis™ platform, designed for the scalable, enzymatic production of RNAi and siRNA therapeutics. In the competitive landscape, Codexis contends with synthetic biology and enzyme specialists such as Novonesis (formerly Novozymes), Ginkgo Bioworks, and Arzeda. Codexis distinguishes itself by moving vertically into integrated oligonucleotide manufacturing, aiming to displace traditional chemical synthesis with more efficient, sustainable enzymatic routes. Originally spun off from Maxygen in 2002, Codexis is now led by a management team with deep pedigree in biomanufacturing and pharmaceutical exits. Dr. Alison Moore, who succeeded Dr. Stephen Dilly as President and CEO in late 2025, brings over two decades of experience from Amgen, Genentech, and Allogene Therapeutics. Dr. Dilly, now serving as Chairman, previously led Sierra Oncology and Aimmune Therapeutics to multi-billion-dollar acquisitions. The executive suite is further bolstered by CFO and Chief Business Officer Georgia Erbez, formerly of Harpoon Therapeutics, and Chief Scientific Officer Dr. Stefan Lutz. The company’s strategic direction is supported by a notable advisory board including RNA pioneer Dr. John Maraganore (founding CEO of Alnylam) and backed by institutional investors and major partners like Merck, which recently secured a $37.8 million supply assurance agreement to stabilize the company’s cash runway through 2027.